EUVIMEDEUVIMED entdecken
Crossref

Impact of Sodium Butyrate Supplementation on Insulin Resistance and Adipose Tissue Modulation in Murine Models of Polycystic Ovary Syndrome

Mariana Muros Ferreira, Yasmin Silva Frank, Giuliana Petri, Juliana Mora Veridiano, Nuha Ahmad Dsouki, Beatriz da Costa Aguiar Alves Reis, Carina Ulsen, Jhonatan Jair Arismendi Florez, Luciano Melo Pompei, Marcelo Luiz Steiner, Bianca Bianco

Gynecologic and Obstetric Investigation · 2026

DOI: 10.1159/000551076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gynecologic and Obstetric Investigation, 2026. Verfasst von Mariana Muros Ferreira und 10 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduation Program in Health Sciences, Faculdade de Medicina do ABC/Centro Universitário FMABC, São Paulo, Brazil. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Insulin Resistance, Butyric Acid, Adipose Tissue.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder affecting up to 10% of women of reproductive age, commonly associated with visceral obesity, insulin resistance, and chronic low-grade inflammation. Sodium butyrate, a microbial-derived short-chain fatty acid, has been proposed as a therapeutic agent due to its anti-inflammatory and metabolic regulatory properties. However, its efficacy under hyperandrogenic and proinflammatory conditions remains uncertain.

Design

Experimental study using female BALB/c mice. Forty animals were allocated into five groups: control (CT), high-fat diet (HFD), dehydroepiandrosterone (DHEA), butyrate without PCOS (BUT), and butyrate with PCOS (DHEA+BUT). Participants/Materials, Setting, Methods: Animals received a high-fat diet (except CT), and hyperandrogenism was induced by DHEA. Sodium butyrate was administered via oral gavage during the last 40 days of the protocol. Body weight, glucose tolerance, adipose tissue mass and morphology, serum adipokines, inflammatory gene expression, and gut microbiota profiles were assessed.

Results

Butyrate-treated groups, particularly DHEA+BUT, exhibited greater body weight gain and significant expansion of subcutaneous, visceral, and brown adipose depots (p < 0.01). Adipose morphometry showed reduced adipocyte number with preserved diameter, indicative of hypertrophy, accompanied by elevated IL-6 and TNF-α expression in visceral fat (p < 0.01). Leptin levels tended to increase, while adiponectin was significantly reduced in the DHEA+BUT group. Glucose tolerance was impaired in all high-fat diet groups, with the BUT group showing the highest glycemic peaks. Although butyrate increased gut microbial diversity, it failed to prevent metabolic or inflammatory dysfunction.

Limitations

The modest number of animals per group reduced statistical power, reflecting constraints in breeding and availability of age-matched BALB/c mice. Their relatively small adipose depots limited tissue yield for molecular and histological assays. Daily oral gavage, required for precise dosing, was technically challenging and led to the loss of one DHEA+BUT animal. Microbiota sequencing was performed in only one animal per group due to high costs, limiting the strength of conclusions regarding microbial changes. Finally, lean mass composition was not directly assessed, although depot weights strongly support adipose expansion.

Conclusions

In this model of pre-established obesity and hyperandrogenism, butyrate supplementation was not metabolically protective. Instead, it was associated with worsened adipose inflammation, altered adipokine profiles, and impaired glucose regulation. These findings highlight the context-dependent nature of butyrate’s effects and caution against its generalization as a universally beneficial metabolic modulator.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeInsulin ResistanceButyric AcidAdipose TissueAnimalsFemaleMiceDisease Models, AnimalMice, Inbred BALB CObesityDiet, High-FatDehydroepiandrosteroneHyperandrogenismDietary Supplements

Stichwörter der Autor:innen

Adipose tissueInsulin resistanceMetabolic inflammationPolycystic ovary syndromeSodium butyrate

Substanzen

Butyric AcidDehydroepiandrosterone

Autor:innen und Institutionen

  • Postgraduation Program in Health Sciences, Faculdade de Medicina do ABC/Centro Universitário FMABC, São Paulo, Brazil.
  • Medical School, Faculdade de Medicina do ABC/Centro Universitário FMABC, São Paulo, Brazil.
  • Animal Facility, Faculdade de Medicina do ABC/Centro Universitário FMABC, São Paulo, Brazil.
  • Department of Morphology and Physiology, Histology Laboratory, Faculdade de Medicina do ABC/Centro Universitário FMABC, São Paulo, Brazil.
  • Multi-User Laboratory, Faculdade de Medicina do ABC/Centro Universitário FMABC, São Paulo, Brazil.
  • Clinical Analysis Laboratory, Faculdade de Medicina do ABC/Centro Universitário FMABC, São Paulo, Brazil.

Zitieren

APA

Ferreira, M. M., Frank, Y. S., Petri, G., Veridiano, J. M., Dsouki, N. A., Reis, B. D. C. A. A., Ulsen, C., Arismendi Florez, J. J., Pompei, L. M., Steiner, M. L., & Bianco, B. (2026). Impact of Sodium Butyrate Supplementation on Insulin Resistance and Adipose Tissue Modulation in Murine Models of Polycystic Ovary Syndrome. Gynecologic and Obstetric Investigation. https://doi.org/10.1159/000551076

Vancouver

Ferreira MM, Frank YS, Petri G, Veridiano JM, Dsouki NA, Reis BDCAA, et al. Impact of Sodium Butyrate Supplementation on Insulin Resistance and Adipose Tissue Modulation in Murine Models of Polycystic Ovary Syndrome. Gynecologic and Obstetric Investigation. 2026. doi:10.1159/000551076

BibTeX
@article{Ferreira2026,
  author = {Ferreira, Mariana Muros and Frank, Yasmin Silva and Petri, Giuliana and Veridiano, Juliana Mora and Dsouki, Nuha Ahmad and Reis, Beatriz da Costa Aguiar Alves and Ulsen, Carina and Arismendi Florez, Jhonatan Jair and Pompei, Luciano Melo and Steiner, Marcelo Luiz and Bianco, Bianca},
  title = {Impact of Sodium Butyrate Supplementation on Insulin Resistance and Adipose Tissue Modulation in Murine Models of Polycystic Ovary Syndrome},
  journal = {Gynecologic and Obstetric Investigation},
  year = {2026},
  doi = {10.1159/000551076}
}
Kostenlos starten →